Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by KayDayon Jan 18, 2011 10:58am
394 Views
Post# 17989327

RE: Questions

RE: QuestionsI was on another computer not logged in and WOW this board is a mess and full of a lot of static when you haven't put a BUNCH of people on ignore.  I truly enjoy this board when you get rid of the trouble makers.  The one good thing is... they usually pull this just before something big is about to happen.

I think it is safe to say that the volume is low because everyone is waiting for a signal.  It won't take much for this to take off when the first big buy comes.  I believe and have been told that there is a lot of news coming. 

As for partnership or funding don't forget...

the short form base shelf prospectus of Stem Cell Therapeutics Corp. (the "Corporation") dated

November ?, 2010 relating to the qualification for distribution of up to $15,000,000 aggregate initial offering price

of common shares, , warrants and/or units of the Corporation (the "Prospectus").

Bullboard Posts